Skip to Main Content
Text size: SmallMediumLargeExtra-Large

John A. Chiorini, Ph.D.

John A. Chiorini, Ph.D.Senior Investigator
Deputy Chief, Adeno-Associated Virus Biology Section

NATIONAL INSTITUTES OF HEALTH/NIDCR
BUILDING 10 ROOM 1N113
10 CENTER DR MSC 1190
BETHESDA MD 20892-1190

Phone: (301) 496-4279
Fax: (301) 402-1228
E-mail: jchiorini@dir.nidcr.nih.gov

Biographical Sketch

Dr. John (Jay) Chiorini received his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz in 1986 and his Ph.D. in genetics from George Washington University in 1993. Afterwards he completed post-doctoral training fellowships at both the National Institutes of General Medical Science (Pharmacology Research and Training Program) and in the National Heart, Lung, and Blood Institute. He joined the NIDCR as a tenure track investigator in 1999 and currently serves as chief of the Adeno-Associated Virus Biology Section, Molecular Physiology and Therapeutics Branch.

Research Interests

Since 1997, his research has focused on the underlying biology associated with viral gene transfer and the development of novel high activity gene transfer vectors. The overall research goal of the AAV Biology Section is to define the interactions of adeno-associated virus (AAV) with its target cell. Our hypothesis is that by understanding these interactions, and the biology of the virus, we can contribute to the use of AAV vectors for gene therapy. The Molecular Physiology and Therapeutics Branch's program on gene transfer to the salivary gland considers AAV vectors to be the most useful vector for clinical studies with this tissue. Staff members focus on two types of interactions: those encompassing viral transduction of the target cell, and those involving the Rep proteins of wild type AAV and their cellular partners. Current projects study:

  • the tropism and transduction pathways of different serotypes of AAV
  • identifying and characterizing new isolates of AAV
  • as well as the engineering of new vectors by selective screening or rational design.

In addition to our research focus on the causes and treatment of autoimmune disease in collaboration with the Sjogren's clinic, application of our gene transfer technology includes delivery of therapeutic genes to the salivary glands, lung, CNS, inner ear, and eye for the treatment of both local and systemic diseases.

Selected Publications

  1. Roescher N, Vosters JL, Yin H, Illei GG, Tak PP, Chiorini JA. Effect of Soluble ICAM-1 on a Sjogren's Syndrome-like Phenotype in NOD Mice Is Disease Stage Dependent. PLoS One. 2011 May 12;6(5):e19962.
  2. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, McCray PB Jr, Chiorini J, Maury W. From the Cover: T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8426-31. Epub 2011 May 2.
  3. Sheffield AM, Gubbels SP, Hildebrand MS, Newton SS, Chiorini JA, Di Pasquale G, Smith RJ. Viral vector tropism for supporting cells in the developing murine cochlea. Hear Res. 2011 Apr 22. Epub ahead of print
  4. Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB. IL17: potential therapeutic
    target in Sjogren's syndrome using adenovirus-mediated gene transfer. Lab Invest. 2011 Jan;91(1):54-62. Epub 2010 Sep 20.
  5. Gao R, Yan X, Zheng C, Goldsmith CM, Afione S, Hai B, Xu J, Zhou J, Zhang C, Chiorini JA, Baum BJ, Wang S. AAV2-mediated transfer of the human aquaporin-1 cDNA restores fluid secretion from irradiated miniature pig parotid glands. Gene Ther. 2011 Jan;18(1):38-42. Epub 2010 Sep 30.
  6. Nguyen CQ, Yin H, Lee BH, Carcamo WC, Chiorini JA, Peck AB. Pathogenic effectof interleukin-17A in induction of Sjogren's syndrome-like disease using
    adenovirus-mediated gene transfer. Arthritis Res Ther. 2010;12(6):R220. Epub 2010 Dec 23.
  7. Yin H, Vosters JL, Roescher N, D'Souza A, Kurien BT, Tak PP, Chiorini JA.
    Location of immunization and interferon-gamma are central to induction of salivary gland dysfunction in Ro60 peptide immunized model of Sjogren's syndrome. PLoS One. 2011 Mar 28;6(3):e18003.
  8. Brindley MA, Hunt CL, Kondratowicz AS, Bowman J, Sinn PL, McCray PB Jr, Quinn K, Weller ML, Chiorini JA, Maury W. Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. Virology. 2011 Jul 5;415(2):83-94
  9. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, Chiorini JA. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med. 2010 Jun;16(6):662-4. Epub 2010 May 9.
  10. Di Pasquale G, Kaludov N, Agbandje-McKenna M, Chiorini JA. BAAV transcytosis requires an interaction with beta-1-4 linked- glucosamine and gp96. PLoS One. 2010 Mar 9;5(3):e9336
  11. Vosters JL, Yin H, Roescher N, Kok MR, Tak PP, Chiorini JA. Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome.
    Arthritis Res Ther. 2009;11(6):R189. Epub 2009 Dec 14
  12. Vosters JL, Landek-Salgado MA, Yin H, Swaim WD, Kimura H, Tak PP, Caturegli P, Chiorini JA. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum. 2009 Dec;60(12):3633-41.
  13. Chiorini JA, Cihakova D, Ouellette CE, Caturegli P.Sjögren syndrome: advances in the pathogenesis from animal models. J Autoimmun. 2009 Nov-Dec;33(3-4):190-6. Epub 2009 Oct 2. Review
  14. Ortolano S, Di Pasquale G, Crispino G, Anselmi F, Mammano F, Chiorini JA. Coordinated control of connexin 26 and connexin 30 at the regulatory and functional level in the inner ear. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18776-81. Epub 2008 Dec 1
  15. Schmidt M, Govindasamy L, Afione S, Kaludov N, Agbandje-McKenna M, Chiorini JA. Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J Virol. 2008 Sep;82(17):8911-6. Epub 2008 Jun 4.

Patents

  • WO2012047093 (A1) Treatment of the Sjogren's Syndrome
  • US2012064038 (A1) Epidermal Growth Factor Receptor (EGFR) and Methods of Use in Adenoviral-Assocaited Virus Type 6 (AAV6) Transduction
  • CA2745131 (A1) AAV5 Vector and Uses Thereof
  • US2010227407 (A1) AAV4 Vector and Uses Thereof
  • WO2006119432 (A2) Isolation, Cloning, and Characterization of New Adeno-Associated Virus (AAV Serotypes 
  • WO2006029196 (A1) Transcytosis of Adeno-Associated Viruses
  • WO2005056807 (A2) Bovine Adeno-Associated Viral (BAAV) Vector and Uses Thereof
  • WO2005056762 (A2) Truncated CMV Promoters and Vectors Containing Same
  • US2007072282 (A1) Bovine Adeno-Associated Viral (BAAV) Vector and Uses Thereof 
  • US2007098690 (A1) Truncated CMV Promoters and Vectors Containing Same 
  • WO2005017101 (A2) Avian Adenoassociated Virus (AAAV) and Uses Thereof 
  • S2007092866 (A1) Avian Adenoassociated Virus and Uses Thereof
  • US2004110266 (A1) Scalable Purification of AAV2, AAV4 or AAV5 Using Ion-Exchange Chromatography 
  • AU9721001 (A) AAV4 Vector and Uses Thereof
  • US2002012997 (A1) Lipid Vesicles Containing Adeno-Associated Virus Rep Protein for Transgene Integration and Gene Therapy 
  • WO0170276 (A2) AAV5 Vector for Transducing Brain Cells and Lung Cells 
  • US6984517 (B1) AAV5 Vector and Uses Thereof
  • US6468524 (B1) AAV4 Vector and Uses Thereof
  • WO9514771 (A1) Vector Systems for the Generation of Adeno-Associated Virus Particles

Share This Page

GooglePlusExternal link – please review our disclaimer

LinkedInExternal link – please review our disclaimer

Print

This page last updated: March 23, 2016